Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
/
InnoCare Pharma
9969
InnoCare Pharma
Concentration Risk And China's Regulatory Scrutiny Will Bar Pipeline Progress
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
HK$8.21
138.7% overvalued
intrinsic discount
16 Aug
HK$19.60
Loading
1Y
330.8%
7D
12.5%
Author's Valuation
HK$8.2
138.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
HK$8.2
138.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-2b
3b
2017
2019
2021
2023
2025
2027
2028
Revenue CN¥2.7b
Earnings CN¥493.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
23.55%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.89%
Calculation
CN¥493.63m
Earnings '28
x
40.23x
PE Ratio '28
=
CN¥19.86b
Market Cap '28
CN¥19.86b
Market Cap '28
/
2.20b
No. shares '28
=
CN¥9.02
Share Price '28
CN¥9.02
Share Price '28
Discounted to 2025 @ 6.89% p.a.
=
CN¥7.39
Fair Value '25
CN¥7.39
Fair Value '25
Converted to HKD @ 1.0899 CNY/HKD Exchange Rate
=
HK$8.05
Fair Value '25
